

Benchmarking prophylaxis with factor concentrates: reference data on annualized bleeding rates in children with severe hemophilia

Authors

Susanna Ranta,^{1,2} Marloes de Kovel,³ Martin Olivieri,⁴ Kathelijn Fischer,^{3,5} Giancarlo Castaman,⁶ Christoph Königs,⁷ Johannes Oldenburg,⁸ Helen Pergantou,⁹ Christoph Male¹⁰ and H. Marijke van den Berg;³ on behalf of the PedNet Study Group

¹Pediatric Coagulation Unit, Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden; ²Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden; ³PedNet Hemophilia Research Foundation, Baarn, the Netherlands; ⁴Pediatric Thrombosis and Hemostasis Unit, Pediatric Hemophilia Centre, Dr. von Hauner Children's Hospital LMU Munich, Germany; ⁵Center for Benign Haematology, Thrombosis and Haemostasis Van Creveldkliniek, University Medical Center Utrecht, Utrecht, the Netherlands; ⁶Center for Bleeding Disorders and Coagulation, Department of Heart, Lung and Vessels, Careggi University Hospital, Florence, Italy; ⁷Goethe University, University Hospital Frankfurt, Department of Paediatrics and Adolescent

Medicine, Germany; ⁸Institute of Experimental Hematology and Transfusion Medicine, University Hospital Bonn, Medical Faculty, University of Bonn, Germany; ⁹Haemophilia Centre/Haemostasis and Thrombosis Unit, Aghia Sophia Children's Hospital, Athens, Greece and ¹⁰Department of Paediatrics, Medical University Hospital of Vienna, Vienna, Austria

Correspondence:
S. RANTA - susanna.ranta@ki.se

<https://doi.org/10.3324/haematol.2025.288101>

Received: April 26, 2025.
Accepted: August 8, 2025.
Early view: August 28, 2025.

©2026 Ferrata Storti Foundation
Published under a CC BY-NC license 

Appendix

The PedNet Study group members and centers

Europe

- MT Alvarèz Román, Unidad de Coagulopatías, Hopital Universitario La Paz, Madrid, Spain
- O Benitez Hidalgo, Hematology Department, Hospital Universitari Vall d'Hebron, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain
- J Blatny, Department of Paediatric Haematology, Children's University Hospital, Brno, Czech Republic (Supported by Ministry of Health, Czech Republic - conceptual development of research organization (FNBr, 65269705))
- M Bührle, Gesundheit Nord, Klinikum Bremen Mitte, Prof.-Hess-Kinderklinik, Bremen, Germany
- M Carvalho, Immunohemotherapy Department, Congenital Coagulopathies Reference, Centro Hospitalar e Universitário São João, E.P.E., Porto, Portugal
- G Castaman, Department of Heart, Lung and Vessels, Careggi University Hospital, Florence, Italy
- H Chambost, APHM, La Timone Children's Hospital, Center for Bleeding Disorders & Aix Marseille Univ, INSERM, INRA, C2VN, Marseille, France
- A Rosa Cid, Unidad de Hemostasia y Trombosis, Hospital Universitario y Politécnico La Fe, Valencia, Spain
- C Eckhardt, Van Creveld Kliniek, University Medical Center Utrecht, Utrecht, The Netherlands
- C Escuriola-Ettingshausen, HZRM Hämostasie-Zentrum Rhein Main GmbH, Frankfurt, Germany
- K Fischer, Van Creveld Kliniek, University Medical Center Utrecht, Utrecht, The Netherlands
- C Van Geet, University Hospitals Leuven, Service of Pediatric Haematology, Leuven, Belgium
- N Grentenort Andersson, Department of Clinical Sciences, Lund University, Lund; Department of Pediatrics and Malmö Centre for Thrombosis and Haemostasis, Skåne University Hospital, Malmö, Sweden
- S Holzhauer, Department of Pediatrics, Division of Oncology and Hematology, Charité Universitätsmedizin Berlin, Berlin, Germany
- M Kartal-Kaess, Division of Pediatric Hematology & Oncology, Department of Pediatrics, Inselspital, University Hospital, University of Bern, Bern, Switzerland
- R Klamroth, Charité Campus Virchow Klinikum, Klinik für Pädiatrie m.S. Onkologie und Hämatologie, Berlin, Germany
- H Knudsen, Oslo University Hospital HF, Oslo, Norway
- C Königs, University Hospital Frankfurt, Department of Paediatrics and Adolescent Medicine, Frankfurt, Germany
- S Långström, New Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
- V Labarque, University Hospitals Leuven, Service of Pediatric Haematology, Leuven, Belgium
- R Ljung, Department of Clinical Sciences - Paediatrics, Lund University, Lund, Sweden
- C Male, Department of Paediatrics, Medical University Hospital of Vienna, Vienna, Austria
- T Stamm Mikkelsen, Department of Pediatrics, University Hospital of Aarhus at Skejby, Aarhus, Denmark
- AC Molinari, Regional Reference Center for Hemorrhagic Diseases, IRCCS Istituto Giannina Gaslini, Genova, Italy
- J Motwani, Department of Haematology, The Children's Hospital, Birmingham, UK
- B Nolan, Department of Paediatric Haematology, Children's Coagulation Centre, Children's Health Ireland at Crumlin, Dublin, Ireland
- R d'Oiron, Centre de Référence de l'Hémophilie et des Maladies Hémorragiques Constitutionnelles, et HITH UMR_S1176 INSERM, Hôpital Bicêtre, APHP Université Paris Saclay, Le Kremlin Bicêtre, France

- J Oldenburg, Institut für Experimentelle Hämatologie und Transfusionsmedizin, Universitätsklinikum Bonn, Germany
- M Olivieri, Pediatric Thrombosis and Hemostasis Unit, Pediatric Hemophilia Center, Dr. von Hauner Children's Hospital, LMU Munich, Munich, Germany
- C Oudot, Centre Regional d'Hémophilie, Centre Hospitalo Universitaire, Toulouse, France
- H Pergantou, Haemophilia Centre/Haemostasis and Thrombosis Unit, Aghia Sophia Children's Hospital, Athens, Greece
- F Pinto, Department of Haematology, Royal Hospital for Sick Children, Yorkhill, Glasgow, UK
- S Ranta, Pediatric Coagulation Unit, Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden
- E Zápotocká, Department of Pediatric Hematology and Oncology, Prague, Czech Republic
- Royal Hospital for Sick Children, Edinburgh, UK*
- Universitäts-Klinik für Kinder- und Jugendheilkunde, Graz, Austria*
- Hemophilia Comprehensive Care Centre, Great Ormond Street Hospital for Children, London, UK*
- Maggiore Hospital Policlinico, A. Bianchi Bonomi Hemophilia and Thrombosis Centre, Milan, Italy*
- Hospital General Unidad de Hemofilia, Hospitales Universitarios Virgen del Rocío, Sevilla, Spain*

* No longer participating as PedNet center

Israel

- S Levy-Mendelovich, National Hemophilia Center Sheba Medical center, Tel Hashomer & Amalia Biron Research Institute of Thrombosis & Hemostasis, Tel Aviv University, Israel
- G Kenet, National Hemophilia Center Sheba Medical center, Tel Hashomer & Amalia Biron Research Institute of Thrombosis & Hemostasis, Tel Aviv University, Israel

Canada

- M Carcao, Division of Haematology/Oncology, Department of Paediatrics, Hospital for Sick Children, Toronto, Canada
- N Mathews, Division of Hematology/Oncology, Hôpital St Justine, Montréal, Canada

Supplementary Table 1. Life threatening bleeds during full prophylaxis

Patient	Hemophilia type	Age (years)	Type of bleed
1	A	2.4	Intracranial bleeding
2	B	3.2	Intracranial bleeding
3	B	3.6	Pharyngeal bleeding
4	B	4.4	Iliopsoas muscle bleeding
5	A	7.2	Intracranial bleeding
6	A	8.8	Iliopsoas muscle bleeding
7	A	9.1	Intracranial bleeding
8	A	10.8	Iliopsoas muscle bleeding
9	A	12.7	Iliopsoas muscle bleeding
10	A	14.9	Iliopsoas muscle bleeding